Cargando…

Inferring protein domains associated with drug side effects based on drug-target interaction network

BACKGROUND: Most phenotypic effects of drugs are involved in the interactions between drugs and their target proteins, however, our knowledge about the molecular mechanism of the drug-target interactions is very limited. One of challenging issues in recent pharmaceutical science is to identify the u...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwata, Hiroaki, Mizutani, Sayaka, Tabei, Yasuo, Kotera, Masaaki, Goto, Susumu, Yamanishi, Yoshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029543/
https://www.ncbi.nlm.nih.gov/pubmed/24565527
http://dx.doi.org/10.1186/1752-0509-7-S6-S18
Descripción
Sumario:BACKGROUND: Most phenotypic effects of drugs are involved in the interactions between drugs and their target proteins, however, our knowledge about the molecular mechanism of the drug-target interactions is very limited. One of challenging issues in recent pharmaceutical science is to identify the underlying molecular features which govern drug-target interactions. RESULTS: In this paper, we make a systematic analysis of the correlation between drug side effects and protein domains, which we call "pharmacogenomic features," based on the drug-target interaction network. We detect drug side effects and protein domains that appear jointly in known drug-target interactions, which is made possible by using classifiers with sparse models. It is shown that the inferred pharmacogenomic features can be used for predicting potential drug-target interactions. We also discuss advantages and limitations of the pharmacogenomic features, compared with the chemogenomic features that are the associations between drug chemical substructures and protein domains. CONCLUSION: The inferred side effect-domain association network is expected to be useful for estimating common drug side effects for different protein families and characteristic drug side effects for specific protein domains.